Results 21 to 30 of about 1,763 (188)

Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study. [PDF]

open access: yesESMO Open
Background: The role of breast surgery in patients with de novo metastatic breast cancer (mBC) and locoregional oligoprogression, either in the breast or locoregional lymph nodes, who previously had a response to systemic treatment is unknown.
Valenza C   +13 more
europepmc   +2 more sources

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial [PDF]

open access: yesFrontiers in Oncology
Purpose/objectivePatients with metastatic melanoma on active systemic therapy can develop isolated disease progression while the majority of disease remains controlled (oligoprogression).
Oded Icht   +17 more
doaj   +2 more sources

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

open access: yesCase Reports in Oncology, 2016
Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative ...
Shao-Lun Lu   +5 more
doaj   +2 more sources

Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis [PDF]

open access: yesOncoImmunology
Some patients with metastatic non-small-cell lung cancer (NSCLC) receiving anti-PD-1 or anti-PD-L1 immune checkpoint inhibitors (ICIs) progress at a few sites while disease elsewhere stays controlled, a pattern consistent with focal, oligo-acquired ...
Ismaell Massalha   +5 more
doaj   +2 more sources

Is Oligometastatic Cancer Curable? A Survey of Oncologist Perspectives, Decision Making, and Communication [PDF]

open access: yesAdvances in Radiation Oncology, 2023
Purpose: Oligometastatic disease (OMD) refers to a limited state of metastatic cancer, which potentially derives benefit from local treatments. Given the relative novelty of this paradigm, oncologist perspectives on OMD are not well established.
Hae Lin Cho, BA   +5 more
doaj   +2 more sources

Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy [PDF]

open access: yesInternational Journal of Breast Cancer, 2017
Purpose. Despite advances in endocrine therapy (ET), metastatic estrogen receptor positive breast cancer (BrCA) remains incurable. Though the mechanisms of resistance to ET have been studied extensively, the anatomic pattern of disease progression ...
Patrick Kelly   +7 more
doaj   +2 more sources

IUC26686-93 Synergistic potential of cabozantinib and radiotherapy in advanced renal cell carcinoma by site of irradiation [PDF]

open access: yesOncologist
Background Cabozantinib is an established treatment for metastatic renal cell carcinoma (mRCC) and may be continued beyond limited radiological progression in selected patients. In oligoprogressive disease, site-directed radiotherapy (
L Formisano   +9 more
europepmc   +2 more sources

Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence [PDF]

open access: yesEuropean Respiratory Review
With the emergence of lung cancer screening programmes and newly detected localised and multifocal disease, novel treatment compounds and multimodal treatment approaches, the treatment landscape of non-small cell lung cancer is becoming increasingly ...
Raphael Werner   +5 more
doaj   +4 more sources

Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report. [PDF]

open access: yesThorac Cancer
Serial re‐biopsy in EGFR‐mutant NSCLC revealed sequential acquired EGFR T790M, MET c.3010C>G exon 14‐related alteration, and RET‐CCDC6 fusion. Mechanism‐guided therapy with almonertinib, almonertinib plus savolitinib, and later selpercatinib plus almonertinib with local radiotherapy achieved prolonged disease control, with survival approaching 50 ...
Zhu Y, Wang C, Hu NL, Wang DH, Wu SK.
europepmc   +2 more sources

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study [PDF]

open access: yesCancers (Basel)
Background/Objectives: We aimed to evaluate the real-world outcomes of first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer, together with the progression patterns, including the management and outcomes of ...
Köylü B   +62 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy